InvestSMART

Algorae Pharmaceuticals Limited (ASX:1AI)

ALERT: Price-sensitive ASX Announcement for 1AI
Current share price for 1AI : $0.013 0 (0%)+
Announcement
Release
18 May 2026 8:54AM
Price at Release
$0.013
Full Release
download
Summary
Algorae Pharmaceuticals Limited, an AI-enabled pharmaceutical company listed on the ASX as 1AI, announced the expansion of its AI drug combination pipeline through the multi-anchor AOS2 program. This program has broadened from a single anchor to 18 anchor drugs, resulting in over 9 million in silico synergy predictions across diverse therapeutic areas. Initial filtering efforts have identified significant synergy predictions and candidate drug combinations for further evaluation. The company plans to incorporate commercial and intellectual property considerations in its curation process to produce a shortlist of candidates for preclinical validation. These efforts align with ongoing discussions with the Peter MacCallum Cancer Centre for independent validation. Alongside its AI drug discovery initiatives, Algorae continues to advance its commercial pharmaceutical operations.
Key Points
  • Algorae Pharmaceuticals has expanded its AI drug combination pipeline with the AOS2 program.
  • The program extends from a single anchor (CBD) to 18 anchor drugs, allowing for a more diversified pipeline.
  • AOS2 generated over 9 million in silico synergy predictions across various drug-drug-cell line combinations.
  • Initial filtering identified over 478,000 synergy predictions and more than 6,000 combinations with predicted synergy.
  • Structured curation is underway, factoring in commercial and intellectual property considerations.
  • Shortlisted candidates will inform independent validation efforts with the Peter MacCallum Cancer Centre.
  • The company continues to progress its commercial pharmaceutical business alongside AI drug discovery.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.